Robert Allen - Sorrento Therape VP RD

All Insiders . USA . 
Stock . Sorrento Therape . Stakeholders . Insider . Robert Allen
SRNE Stock  USD 0  0.0005  16.67%   

Insider

Robert Allen is VP RD of Sorrento Therape
Phone858 203 4100
Webhttps://www.sorrentotherapeutics.com

Sorrento Therape Management Efficiency

The company has return on total asset (ROA) of (0.4082) % which means that it has lost $0.4082 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (3.7892) %, meaning that it created substantial loss on money invested by shareholders. Sorrento Therape's management efficiency ratios could be used to measure how well Sorrento Therape manages its routine affairs as well as how well it operates its assets and liabilities.
Sorrento Therape currently holds 134.5 M in liabilities with Debt to Equity (D/E) ratio of 1.51, which is about average as compared to similar companies. Sorrento Therape has a current ratio of 1.32, which is within standard range for the sector. Debt can assist Sorrento Therape until it has trouble settling it off, either with new capital or with free cash flow. So, Sorrento Therape's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Sorrento Therape sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Sorrento to invest in growth at high rates of return. When we think about Sorrento Therape's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Robert RooneyMorgan Stanley
52
Erika JamesMorgan Stanley
50
Aya KawazoeNomura Holdings ADR
N/A
Massad EyalValens
66
Victor ChuNomura Holdings ADR
63
Hironori KamezawaMorgan Stanley
58
Yutaka MukiNomura Holdings ADR
N/A
Michael LinseValens
45
Alon BenzarayValens
54
Kazuya KumekawaNomura Holdings ADR
N/A
Adi YarelToledanoValens
46
Hiroshi TanigakiNomura Holdings ADR
N/A
Marc SgaraglinoMorgan Stanley
N/A
Takako MoriNomura Holdings ADR
N/A
Toshiya YoshidaNomura Holdings ADR
N/A
Will BillingsGlobalfoundries
N/A
Andrew SapersteinMorgan Stanley
57
Pradheepa RamanGlobalfoundries
43
Kenji TeshimaNomura Holdings ADR
N/A
Stephen LuczoMorgan Stanley
64
Yoshihiro NamuraNomura Holdings ADR
N/A
Sorrento Therapeutics, Inc., a clinical stage and commercial biopharmaceutical company, develops therapies for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. The company was founded in 2006 and is based in San Diego, California. Sorrento Therpt operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 799 people. Sorrento Therape [SRNE] is traded as part of a regulated electronic over-the-counter service offered by the NASD.

Management Performance

Return On Equity-3.79
Return On Asset-0.41

Sorrento Therape Leadership Team

Elected by the shareholders, the Sorrento Therape's board of directors comprises two types of representatives: Sorrento Therape inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Sorrento. The board's role is to monitor Sorrento Therape's management team and ensure that shareholders' interests are well served. Sorrento Therape's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Sorrento Therape's outside directors are responsible for providing unbiased perspectives on the board's policies.
Mark Brunswick, VP Affairs
Scott Schaus, Chief Officer
Xiao MD, Pres ACEA
Robert Allen, VP RD
Brian Cooley, Sr BU
Shawn Sahebi, VP Operations
Henry Ji, Co-Founder, CEO and President and Director
Alexis DVM, VP BU
William BSc, VP Devel
Elizabeth MBA, CFO VP
JD MD, SVP Officer

Sorrento Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Sorrento Therape a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity-3.79
Return On Asset-0.41
Operating Margin(5.11) %
Current Valuation129.17 M
Shares Outstanding551.28 M
Shares Owned By Insiders0.80 %
Shares Owned By Institutions0.03 %
Number Of Shares Shorted64.56 M
Price To Earning41.15 X
Price To Book4.01 X

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
RSIRush Street Interactive
OKTAOkta Inc
BACBank of America

Other Information on Investing in Sorrento OTC Stock

Sorrento Therape financial ratios help investors to determine whether Sorrento OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Sorrento with respect to the benefits of owning Sorrento Therape security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY